Browse

Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.

U.S. clinical trials continue to lose ground to China, but is Operation Trialblazer enough to help America catch up?

Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted the outlook of rival drugs from Alnylam and BridgeBio Pharma.